Skip to main content

Central Retinal Vein Occlusion clinical trials at UCSF
1 in progress, 0 open to new patients

  • Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

    Sorry, in progress, not accepting new patients

    SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.

    San Francisco, California and other locations